华海药业 (600521.SH)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(华海药业)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2023年第三季度2023年第二季度2023年第一季度2022年第四季度2022年第三季度2022年第二季度2022年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 1,913,434,539.862,235,216,902.902,058,913,113.432,427,793,608.672,014,478,938.612,050,864,644.021,772,607,601.98
 营业收入(元) 1,913,434,539.862,235,216,902.902,058,913,113.432,427,793,608.672,014,478,938.612,050,864,644.021,772,607,601.98
二、营业总成本(元) 1,709,667,477.361,736,009,172.461,791,603,923.391,929,142,722.721,628,020,698.461,499,824,229.751,578,705,956.71
 营业成本(元) 835,657,535.38865,130,511.38846,731,344.65856,783,949.23800,883,736.88773,380,856.83679,887,738.00
 研发费用(元) 239,998,683.66225,253,209.70202,193,404.97255,052,408.82230,655,915.37222,459,699.89217,360,827.03
 营业税金及附加(元) 25,216,526.3323,259,662.2325,582,077.0318,634,144.0320,271,187.3318,649,862.5718,766,269.40
 销售费用(元) 245,862,428.85383,869,117.81344,775,680.27225,956,909.88369,902,192.66291,091,094.26357,286,390.47
 管理费用(元) 297,413,392.07324,369,231.03284,467,860.37457,324,319.47300,629,414.67281,372,210.91250,177,624.33
 财务费用(元) 65,518,911.07-85,872,559.6987,853,556.10115,390,991.29-94,321,748.45-87,129,494.7255,227,107.49
  其中:利息费用(元) 57,349,703.6159,656,765.5864,873,885.0956,553,212.8355,252,057.9552,780,392.4155,432,642.37
  其中:利息收入(元) 9,473,298.5713,937,111.3610,010,646.645,322,771.666,966,681.257,181,918.756,359,774.62
 资产减值损失(元) 7,122,907.23-7,040,649.19-51,261.25-64,858,322.10-3,075,305.90-2,639,638.44-31,226.41
 信用减值损失(元) 7,318,604.21-5,870,280.22-2,268,191.50-17,011,427.35-12,651,077.62-17,731,239.612,026,661.24
三、其他经营收益
 加:公允价值变动收益(元) 2,112,700.91-58,908,922.23-28,119,989.22109,698,688.28-52,041,042.02-42,223,913.65-10,232,705.18
 加:投资收益(元) -34,253,220.23-9,256,440.25-11,291,560.61-39,916,654.59-17,685,154.72-12,556,823.58-5,046,413.05
  其中:对联营企业和合营企业的投资收益(元) -6,254,808.91-4,174,310.08-11,140,267.97-5,633,648.31-13,300,354.72-12,735,949.21-10,521,213.05
 资产处置收益(元) -517,931.47412.99-25,748.84-25,373.8814,476.88-42,002.813,643,399.94
 其他收益(元) 44,748,892.8032,319,618.4018,031,370.6330,295,237.8828,630,750.1024,076,019.8216,503,258.66
四、营业利润(元) 230,299,015.95450,451,469.94243,583,809.25516,833,034.19329,650,886.87499,922,816.00200,764,620.47
 加:营业外收入(元) 916,387.662,135,283.67669,939.991,927,737.57612,939.30276,230.72816,683.28
 减:营业外支出(元) 8,711,658.728,006,835.013,370,103.5633,474,094.911,670,091.903,108,509.913,652,475.52
五、利润总额(元) 222,503,744.89444,579,918.60240,883,645.68485,286,676.85328,593,734.27497,090,536.81197,928,828.23
 减:所得税费用(元) 72,135,622.5850,275,603.1872,378,253.42113,664,712.77100,509,553.5460,665,239.3258,050,797.67
六、净利润(元) 150,368,122.31394,304,315.42168,505,392.26371,621,964.08228,084,180.73436,425,297.49139,878,030.56
(一)按经营持续性分类
  持续经营净利润(元) 150,368,122.31394,304,315.42168,505,392.26371,621,964.08228,084,180.73436,425,297.49139,878,030.56
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 152,736,902.41395,884,864.88172,934,924.85373,239,856.49226,521,940.42430,295,279.66137,701,672.91
  少数股东损益(元) -2,368,780.10-1,580,549.46-4,429,532.59-1,617,892.411,562,240.316,130,017.832,176,357.65
 扣除非经常性损益后的净利润(元) 146,964,128.94433,302,371.95188,552,713.22314,721,846.57254,881,436.49452,832,420.17130,630,395.31
七、每股收益
 一、基本每股收益(元) 0.110.270.120.260.160.290.10
 二、稀释每股收益(元) 0.110.270.120.250.160.290.10
八、其他综合收益(元) -1,271,319.028,006,100.87-2,509,362.696,600,919.76-6,517,808.51-3,210,179.17-102,951.74
 归属于母公司股东的其他综合收益(元) -1,275,679.389,425,037.48-2,258,971.896,771,107.66-6,919,584.80-3,717,983.41-50,234.73
 归属于少数股东的其他综合收益(元) 4,360.36-1,418,936.61-250,390.80-170,187.90401,776.29507,804.24-52,717.01
九、综合收益总额(元) 149,096,803.29402,310,416.29165,996,029.57378,222,883.84221,566,372.22433,215,118.32139,775,078.82
 归属于母公司所有者的综合收益总额(元) 151,461,223.03405,309,902.36170,675,952.96380,010,964.15219,602,355.62426,577,296.25137,651,438.18
 归属于少数股东的综合收益总额(元) -2,364,419.74-2,999,486.07-4,679,923.39-1,788,080.311,964,016.606,637,822.072,123,640.64
公告日期 2023-10-312023-08-312023-04-292023-04-292022-10-292022-08-312022-04-26
审计意见(境内) 标准无保留意见

前瞻产业研究院